RANBP9

Across TCGA pan-cancer cohorts, RANBP9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RANBP9 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RANBP9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RANBP9 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where RANBP9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.616	0.877	.004	23	view →
LSCC	DFS	Median	All	0.991	0.892	.009	5	view →
HNSC	DFS	Median	All	0.325	0.875	.010	4	view →
CCRCC	DFS	Tertile	II,III,IV	0.752	0.908	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RANBP9–PDAC (DFS)

Open the PDAC breakdown →